Jun 08, 2026
Zealand Pharma (ZEAL) Plummets 25% on Survodutide Tolerability Concerns
Zealand Pharma (ZEAL) stock plunged 25% after survodutide obesity trial showed 1 in 4 patients quit due to GI side effects despite strong weight loss data.
The post Zealand Pharma (ZEAL) Plummets 25% on Survodutide Tolerability Concerns appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Semiconductor Stocks Tumble: Nvidia (NVDA), AMD, and Micron Face Sharp Declines
- 1 hour ago
Microsoft (MSFT) Stock: Chevron Partnership Powers AI Data Center Expansion Stra...
- 2 hours ago
IBM (IBM) Stock Surges 4% on JPMorgan Upgrade and Presidential Quantum Support
- 2 hours ago
Intel (INTC) Stock Receives $160 Price Target as BofA Sees Strengthening Fundame...
- 2 hours ago
Tesla (TSLA) Stock Under Scrutiny as NHTSA Probes Deadly FSD Crash in Texas